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Synthetic glycopeptides have the potential to detect antibodies in multiple sclerosis (MS). In the present study, we analyzed the antibodies
(IgM class, IgG class and IgG subclasses) to the synthetic glycopeptide CSF114(Glc) in the serum of 186 MS patients, 166 blood donors
(BDs), 25 patients affected by meningitis/encephalitis, 41 affected by systemic lupus erythematosus (SLE) and 49 affected by rheumatoid
arthritis (RA). The IgM antibody level to CSF114(Glc) was significantly increased in MS patients versus BDs ( p <0.001) or versus other
autoimmune diseases (SLE or RA, p <0.001). The IgG response was restricted to the subclass IgG2. IgM antibodies to CSF114(Glc) were
found in 30% of relapsing/remitting MS patients and, at lower levels, in subjects affected by meningitis/encephalitis. The study of antibodies
to CSF114(Glc) is a new, potential immunological marker of MS.
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Multiple sclerosis (MS) is an autoimmune disease with
an unpredictable course and a difficult prognostic evalua-0165-5728/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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E-mail address: lolli@unifi.it (F. Lolli).tion. The pathology of MS is believed to be heterogeneous
and different effector immune mechanisms may lead to the
formation of inflammation and demyelination within the
central nervous system (CNS) lesions (Kornek and
Lassmann, 2003; Lassmann et al., 2001). Magnetic
resonance imaging (MRI) has proven to be a sensitive
technique in detecting MS lesions and it is the only
accepted marker of the disease (Fazekas et al., 1999).
Nonetheless, understanding the relationship between they 167 (2005) 131 – 137
Table 1
Demographic and clinical characteristics of 186 MS patients
Age, range (median) 17–69 (39)
Females, number (%) 156 (84%)
EDSS, range (median) 0–8.5 (3)
Disease duration, range (median) 1 months–34 years
(9 years)
Patients in relapsea 42 (22%)
Clinical form:
Relapsing/Remitting 156 (84%)
Secondary progressive 21 (11%)
Relapsing progressive 8 (4%)
Primary progressive 1 (1%)
Treatments:
None 47 (25%)
Interferon-h, glatimer acetate or azathioprine 139 (75%)
Treatment duration, range (median) 15 days–4 years
(1.5 years)
a A relapse was recorded within the 3 months preceding the blood
sampling.
F. Lolli et al. / Journal of Neuroimmunology 167 (2005) 131–137132detection of MRI changes and brain pathology is at present
incomplete (Wayne Moore, 2003). Therefore, it is essential
to identify new markers able to help in management of the
disease. Not surprisingly, just a few immune tests have
been linked to a specific pathogenetic step of the disease
(Bielekova and Martin, 2004).
In the past decade, a large body of evidence has
highlighted the important role of autoreactive B cells and
autoantibodies in the course of MS, at least in relapsing/
remitting (RR) patients (Cross et al., 2001). Interesting
results were obtained studying the autoantibody response
in experimental allergic encephalomyelitis (EAE), whereas
antibodies to myelin glycoproteins can induce significant
and prominent demyelination and severe disease (Glynn
and Linington, 1989; Linington et al., 1988). Previous
findings also support this pathogenetic mechanism in
humans. First, oligoclonal IgG are synthesized in brain
lesions and diffuse into cerebrospinal fluid (CSF), an
alteration considered of diagnostic and prognostic value in
MS (Link et al., 1973). Second, serum IgM antibodies to
myelin oligodendrocyte glycoprotein (MOG) and myelin
basic protein (MBP), the best candidate targets for
demyelinating antibodies, were recently shown to have a
predictive value indicating a new relapse in the initial
phase of MS (Berger et al., 2003). MOG is the only
myelin protein able to induce both encephalitogenic T cell
responses and demyelinating antibodies (Lindert et al.,
1999). However, new antibody specificities are being
continuously discovered in MS, using recombinant pro-
teins or new proteomic assays (Almeras et al., 2004). From
another point of view, these methodologies may fail to
expose relevant epitope structures, such as in oligosac-
charide or in post-translationally modified antigens (Doyle
and Mamula, 2001). This may be a reason for the
discrepancies in results employing linear peptides and
recombinant proteins versus natural antigens (Mantegazza
et al., 2004).
We reported that glycopeptides were able to detect
autoantibodies in MS (Mazzucco et al., 1999; Carotenuto
et al., 2001), demonstrating, for the first time, the
possibility of using a glycosylated peptide to identify
autoantibodies in humans. The data further suggest the use
of modified peptides as synthetic antigens in solid-phase
ELISA to expose a conformational structure to the
antibodies (Carotenuto et al., 2001). We developed a
synthetic glycopeptide, called CSF114(Glc), able to opti-
mize the recognition of antibodies in MS patient serum
(Papini et al., 2002). In the present study, we report the
occurrence of serum antibodies to CSF114(Glc) (IgM class,
IgG class and IgG subclasses) in a large group of MS
patients and compared the results with other inflammatory/
infectious nervous system disorders and other autoimmune
diseases. The results obtained in MS were also correlated
to disease duration, disability, different clinical course of
the disease (i.e., relapsing versus progressive forms of MS)
and treatments.2. Materials and methods
2.1. Serum and cerebrospinal fluid collection
Serum was obtained for diagnostic purposes between
1998 and 2003 from patients and healthy BDs who had
given their informed consent, and stored at 20 -C until
use. Paired samples of CSF and serum were obtained
from a group of MS patients after a diagnostic lumbar
puncture.
2.2. Patients
The selected MS patients (n =186), from different MS
centers, fulfilled established international diagnostic
criteria (Poser et al., 1983). The age of onset was
between 10 and 50 years. The clinical findings, the
EDSS and the clinical course of MS (Kurtzke, 1983;
Lublin and Reingold, 1996) were evaluated at the time
of blood sampling. CSF and MRI examinations were
performed for diagnostic purposes. All patients received
a course of steroids during relapse. The demographic and
clinical characteristics of these patients are shown in
Table 1.
As the control, we employed 166 blood donors (BDs), 25
patients affected by meningitis/encephalitis with a typical
CSF pleocytosis used as an inflammatory neurological
disease (IND) control and, as a control for other auto-
immune diseases, we employed 41 patients affected by
systemic lupus erythematosus (SLE) and 49 patients
affected by rheumatoid arthritis (RA).
We detected the subclass restriction of IgG in patients
presenting increased levels of IgG antibodies to
CSF114(Glc). For this purpose, we selected 14 MS, 3
IND and 13 BD subjects with different levels of increased
IgG antibody absorbance to CSF114(Glc).
F. Lolli et al. / Journal of Neuroimmunology 167 (2005) 131–137 133The antibodies were also measured in paired samples of
CSF and serum obtained from a different group of 34 RR
MS patients.
2.3. Preparation of CSF114(Glc)
CSF114(Glc) is a synthetic 21 amino acid residue
glycopeptide, bearing a glucosyl moiety N-linked to an
Asn residue. The sequence of the peptide and its specific
glycosylation pattern (Papini et al., 2003) were selected
from focused libraries of synthetic glycopeptides on the
basis of their ability to specifically recognize autoanti-
bodies in MS patient sera, using an immunoenzymatic
assay. The glycopeptides were prepared by solid-phase
peptide synthesis and purified to homogeneity by
preparative high-pressure liquid chromatography (HPLC).
The identity and the purity of the final product were
checked by mass spectrometry and analytical HPLC
(Papini et al., 2002).
2.4. Determination of serum antibodies by ELISA
Ninety-six well activated polystyrene ELISA plates
(Limbro Titertek, ICN Biomedicals, Inc., Aurora, Ohio,
USA) were coated with 1 Ag/well of CSF114(Glc) in pure
carbonate buffer 0.05 M (pH 9.6) and incubated at 4 -C
overnight. After 5 washes in an automated ELISA washer
(Columbus, Tecan, Austria) with saline containing 0.05%
Tween 20, the plates were blocked by 10% fetal calf serum
(FCS) in saline Tween (100 Al/well) at room temperature
(RT) for 60 min. Sera diluted 1:100 and 1:2000 were
applied at 4 -C for 16 h in saline Tween 10% FCS (2
dilutions were tested for each individual serum). After 5
washes, 100 Al/well of alkaline phosphatase conjugated
anti-human IgM or anti-human IgG Fab2-specific affinity
purified antibody (Sigma, I0759/I9885, Saint Louis,
Missouri, USA), diluted 1:400 (anti-IgM) or 1:2000
(anti-IgG) in saline Tween/FCS were added. After 3 h
incubation at RT and 5 washes, 100 Al of substrate solution
consisting of 2 mg/ml of p-nitrophenylphosphate (pNPP
tablets N2765, Sigma, Saint Louis, Missouri, USA) in10%
diethanolamine buffer was applied. The reaction was
blocked after 30 min with 50 Al of 1 M NaOH and the
absorbance read in a multi-channel ELISA reader at 405
nm (Sunrise, Tecan, Austria). ELISA plates, coating
conditions, reagent dilutions, buffers and incubation times
were tested in preliminary experiments. Each plate
included at least 2 positive and 2 negative controls. Each
serum was individually evaluated at 2 dilutions (1:100 and
1:2000) to control the parallelism and dilution of antibody
absorbance between the reference positive samples and the
unknowns. Subclass specific mouse anti-human IgG
conjugates (IgG1 9052-04, IgG2 9060-04, IgG3 9210-04,
IgG4 9200-04, Southern Biotech, Birmingham, Alabama,
USA) were used (diluted 1:1000) to detect the IgG
subclass specific response. The antibody levels revealedby ELISA were expressed both as an absorbance value at a
dilution of 1:100 and as a titer (sample dilution which
reaches the average plus three standard deviations of
blanks). The analytical variability of the assays was
evaluated repeating the same test (IgM and IgG determi-
nations) in the same run (4 sera, 20 determinations each)
or in different experiments (4 sera, 10 experiments on
different days). The within-assay and between-assay
coefficients of variation (SE/mean) were below 10%
(IgM) or below 5% (IgG).
The cut-off values, employed to separate the results
between BD and MS samples, were set for the IgM class
in a ROC analysis, comparing different cut-off values as
sensitivity, specificity and likelihood ratios (Habbema et
al., 2002). The IgM cut-off was set at a level (absorbance
0.7) maximizing sensitivity, specificity and likelihood
ratios. The IgG cut-off value was arbitrarily set at
absorbance 1. The CSF samples (n =34) were tested at
1:2 and 1:20 dilutions and the intrathecal synthesis of the
antibodies in the CSF was evaluated employing the
antibody index (Reiber and Lange, 1991).
2.5. Statistical analysis
The descriptive statistical analysis, the heterogeneity
tests, the difference between parametric data or catego-
rical variables and the linear regression and correlations
were evaluated using StatView or GraphPad Prism
statistical analysis software. To test for the heterogeneity
of the results in different MS groups, we employed the
Bartlett test to compare the variances observed in
different groups (sex, different clinical form of the
disease, disease activity and therapy). Due to hetero-
geneity of the data, we employed a distribution inde-
pendent analysis. Within-group comparisons were
performed with the non-parametric Kruskal–Wallis one-
way analysis of variance (ANOVA), employing the Dunn
multiple comparison test for post-analysis group compar-
ison. The differences between frequencies of abnormal-
ities revealed in different diagnostic groups were analyzed
employing the Fisher Exact Test. The significance of the
P values was set at <0.05.3. Results
3.1. IgM antibodies to CSF114(Glc) in serum
The heterogeneity Bartlett test showed that the IgM
antibody absorbance to CSF114(Glc) was heterogeneous
between the various diagnostic groups. We employed a
distribution independent analysis to compare the antibodies
between the groups. The IgM antibody absorbance to
CSF114(Glc) was higher in MS (median 0.49) compared
to the BD (median 0.27, Dunn test, p <0.001), RA (median
0.38, p <0.001) and SLE (0.26, p <0.01) subjects. The
Fig. 1. Column scatter and median values of IgM (upper panel) and IgG
(lower panel) antibody absorbance (102, dilution 1:100) to CSF114(Glc)
in multiple sclerosis (MS, n =186), blood donors (BD, n =166), patients
affected by meningitis/encephalitis (inflammatory neurological disease
control, IND, n =25), systemic lupus erythematosus (SLE, n =41) and
rheumatoid arthritis (RA, n =49). IgM antibody level to CSF114(Glc) is
significantly increased in MS patients versus blood donors (Fisher Exact
Test p =0.005) and versus RA ( p =0.001) or SLE ( p <0.001). The
horizontal lines indicate the selected cut-off values for IgM and IgG
determination and the median value of each group.
Fig. 2. ROC curve analysis of IgM antibodies to CSF114(Glc) in MS versus
BD. The area under the curve is 0.73 ( p <0.03). The cut-off point was set at
an absorbance of 0.7 with a sensitivity of 26%, a specificity of 94%, and a
positive likelihood ratio of 4.46.
Fig. 3. IgG1, IgG2, IgG3 and IgG4 antibody absorbance to CSF114(Glc) in
14 MS, 13 BD and 3 IND subjects presenting the IgG antibody. All of the
antibody reactivity is restricted to IgG2.
F. Lolli et al. / Journal of Neuroimmunology 167 (2005) 131–137134column scatter of the data is reported in Fig. 1 (upper
panel). Although the differences between the MS and IND
subjects were not statistically significant, the highest
values of antibody absorbance (>1.3) were observed only
in MS subjects. The ROC curve constructed to evaluate
different cut-off values and separate the results observed
between BD and MS subjects is reported in Fig. 2 (area
under the curve 0.73, p <0.03). At an absorbance cut-off
level of 0.7, we obtained a sensitivity of 26% (95%
confidence interval (CI) between 20% and 32%), a
specificity of 94% (89% to 97%) and a likelihood ratio
of positives of 4.46 (95% CI 2.3 to 8.5). Considering the
frequency of an increased IgM antibody level for
CSF114(Glc) in the different diagnostic groups, the anti-
bodies were detected in 50 MS patients (26%) versus 10
BDs (6%, Fisher Exact Test p=0.005). Compared to the
BDs, increased levels were also found in 5/25 IND (20%)
subjects, although only with lower absorbance values. NoIgM antibodies to CSF114(Glc) were detected in patients
with RA (5/49) or SLE (1/41).
3.2. IgG antibodies to CSF114(Glc) in serum
The levels of IgG absorbance are reported in Fig. 1
(lower panel). The differences between MS and BD or the
other groups were not significant.
3.3. IgM and IgG antibodies to CSF114(Glc) in CSF
The IgM antibodies to CSF114(Glc) were not detectable
in the CSF (absorbance <0.04). The IgG antibodies in CSF
were detected in 5/36 patients presenting the highest levels
of IgG absorbance to CSF114(Glc) in serum, with no
evidence of intrathecal synthesis of the antibodies, accord-
ing to the antibody index formula.
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A total of 83 MS patients (44%) presented IgG and/or
IgM antibodies to CSF114(Glc) compared to 42 BDs (18%,
Fisher Exact Test, p<0.0002).
3.5. IgG 2 subclasses in MS and BD subjects
In 14 MS, 13 BD and 3 IND subjects, selected for
presenting IgG antibodies, the antibodies were entirely
restricted to the IgG2 subclass (Fig. 3).
3.6. Correlation to clinical variables
The heterogeneity Bartlett test showed that the IgM
antibodies to CSF114(Glc) as well as the EDSS score and
duration were not homogeneous in RR versus progressive
MS patients, while no differences were detectable in relation
to sex, disease clinical activity or therapy.
Evaluating the results as frequency of antibody reactivity,
IgM positives to CSF114(Glc) were found in the serum of
46/156 (30%) RR MS patients compared to 2/21 (9%)
secondary progressive patients only (Fisher Exact Test,
p =0.07). No significant differences were detected in
relation to disease clinical activity or therapy.
When correlating the antibody reactivity to CSF114(Glc)
and disease duration or disability (Fig. 4), the highestFig. 4. Correlation between IgM absorbance (102, dilution 1:100) in
serum to CSF114(Glc), disease duration (upper panel) and EDSS disability
score (lower panel) in 156 relapsing/remitting MS patients. The linear
correlation between increased IgM levels and disease duration or EDSS
score is not significant.antibody levels were found in RR patients with an EDSS
score between 0 and 4 and a disease duration between 5 and
15 years. However, no significant linear correlation could be
revealed between the antibodies and disease duration or
EDSS scores.4. Discussion
After intensive research, the targets of the putative B
cell autoantibodies in MS are growing in numbers (Cross
et al., 2001), and involve multiple structures in individual
patients. It is possible that the pathogenic responses are
hidden by irrelevant ones (Mathey et al., 2004). We
considered that oligosaccharides are key epitopes in a
number of clinically important antigenic structures, such as
those in blood group determinants, xenotransplantation
antigens or tumors, but have not yet been adequately
studied in MS (Delves, 1998). We applied a chemical
approach to the synthesis of a highly reproducible
glycopeptide structure, optimized in parallel to an immu-
nological detection using ELISA, able to reveal antibodies
in MS that recognize a specific conformational epitope
(Craig et al., 1998; Dharmasaroja, 2003). This enabled the
reproducible and effective detection of IgM autoantibodies
to glycopeptide CSF114(Glc) in a significant proportion
(30%) of the RR MS patients, and with a high specificity
for this disease (94%), i.e., no antibody reactivity was
detected in other autoimmune diseases or other infective
neurological diseases. Some patients with meningitis or
encephalitis presented increased levels of antibodies.
However, it should be considered that this result is not
surprising as these diseases are usually employed as a
control for autoimmune reactivity in serum during active
acute neuro-inflammation and demyelination. This latter
condition was already clearly associated to the activation
of the autoantibody response to various myelin, viral, and
bacterial antigens (Vartdal et al., 1980). The IgM reactivity
to CSF114(Glc) in patients with meningo-encephalitis was,
however, lower than in MS, confirming the specificity of
the increased antibodies for MS.
Studying the clinical correlation of autoantibodies is an
important step in characterizing the possible pathogenicity
of the autoimmune response. Although the clinical/immu-
nological correlations are difficult to detect in the cross-
sectional studies (Karni et al., 1999), the antibodies
detected in the present study were typical of RR patients,
with a tendency toward the highest antibody absorbance
after a disease duration between 5 and 15 years and with a
low-medium disability, a disease phase associated to a
predominant inflammation-demyelination within the nerv-
ous system (Lassmann, 2002; Compston and Coles, 2002).
From a different point of view, IgM to myelin components
may also be considered as having a possible protective role
(Rosenbluth et al., 2003). No significant alterations were
revealed in relation to disease activity and treatments.
F. Lolli et al. / Journal of Neuroimmunology 167 (2005) 131–137136However, the majority of MS patients are presently
subjected to a heterogeneous set of immunomodulating/
immunosuppressive treatments and steroidal pulses, while
only a few patients are left untreated, and these differences
are difficult to detect.
The IgG antibodies produced in MS are usually
restricted to IgG1 and IgG3 subclasses (Vandvik et al.,
1976). In contrast with these previous results and as
expected from the chemical structure of the antigen, the
response to CSF114(Glc) was limited to the IgG2 subclass,
a subclass characteristic of a T cell independent response to
glycoepitopes and rarely found, until now, in MS (Garcia-
Merino et al., 1986; Mathiesen et al., 1989; Egg et al.,
2001). From this point of view, bacterial products, such as
those containing polysaccharides, were detected in brain
lesions and linked to B and T cell stimulation (Schrijver et
al., 2001) and activation of inflammatory responses
(Matyszak, 1998). In addition, it has already been shown
that B cell activation in MS may be dependent on bacterial
as well as viral antigens (Persson et al., 1989). An
increasing number of mimicries between bacterial proteins
and myelin antigens have been documented, suggesting a
pathogenetic link between the antibody responses to
bacterial carbohydrate products and those to myelin
antigens (Hughes et al., 2003; Yuki et al., 2004). From
another point of view, as glycosylation changes occur in
different autoimmune diseases, many studies have recently
focused on the role of immune responses to modified
structures in autoimmune diseases and MS (Doyle and
Mamula, 2001). An alternative hypothesis is based on the
immune recognition of an altered brain glycoprotein. The
difficulties of detecting an intrathecal response to
CSF114(Glc) seem to contradict this hypothesis and further
studies are needed to investigate the possibility of an
antibody-mediated demyelination.
We should acknowledge that antibodies to myelin
antigens or glycoepitopes are difficult to detect, are not
consistently found in MS, and there are significant
discrepancies between studies, particularly when taking
into account the efforts needed for result standardization
between laboratories (Mantegazza et al., 2004; Lampasona
et al., 2004). Our results indicate, for the first time, the
possibility of identifying a subgroup of MS patients with
systemic antibody synthesis and a high specificity of
response for MS. The discovery of an antibody response in
MS specifically involving the IgM class is not surprising.
IgM antibodies to oligodendrocyte structures were recently
found to bind to glial cell membranes and induce calcium
signaling. The biological importance of IgM reacting to
different glycoepitopes was further confirmed in an
experimental model in which the antibodies are synthe-
sized within the CNS and play a different and contrasting
role in demyelination versus remyelination ‘‘in situ’’
(Rosenbluth et al., 2003). The exact definition of the
antibody epitope, clarification of the antigens inducing the
response, and a longitudinal study of B cell activation tothe glycosylated epitope of CSF114(Glc) in individual
patients will clarify the issue on the relevance and
prognostic value of the antibodies to CSF114(Glc) in the
follow-up of MS.5. Disclosures
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